2020
DOI: 10.3390/ijerph17041395
|View full text |Cite
|
Sign up to set email alerts
|

Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature

Abstract: Antimicrobial resistance (AMR) has become a global threat to not only public health impacts but also clinical and economic outcomes. During the past decades, there have been many studies focusing on surveillance, mechanisms, and diagnostics of AMR in infectious diseases but the impacts on public health, clinical and economic outcomes due to emergence of these AMRs are rarely studied and reported. This review was aimed to summarize the findings from published studies to report the outcome impacts due to AMR of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
13
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(13 citation statements)
references
References 86 publications
0
13
0
Order By: Relevance
“…When these costs were applied to the 364 MDR-TB and nine XDR-TB, huge approximate amounts of $53 million direct costs and $100 million direct plus productivity loss costs came to surface. A prospective dynamic state transition model study from China indicated that by 2050 the MDR-TB incidence and mortality will increase to 60% and 35% respectively, while the same parameters for DS-TB drop by 32% and 41%, respectively, due to the high treatment and cure rates, while the worsening of situation for the MDR-TB is attributable to high transmission, increased prevalence, and in appropriate treatment of LTBI [ 148 ]. The price factor in certain countries remains a critical factor for the MDR-TB medicines that are very costly in certain countries.…”
Section: Public Health Concernsmentioning
confidence: 99%
“…When these costs were applied to the 364 MDR-TB and nine XDR-TB, huge approximate amounts of $53 million direct costs and $100 million direct plus productivity loss costs came to surface. A prospective dynamic state transition model study from China indicated that by 2050 the MDR-TB incidence and mortality will increase to 60% and 35% respectively, while the same parameters for DS-TB drop by 32% and 41%, respectively, due to the high treatment and cure rates, while the worsening of situation for the MDR-TB is attributable to high transmission, increased prevalence, and in appropriate treatment of LTBI [ 148 ]. The price factor in certain countries remains a critical factor for the MDR-TB medicines that are very costly in certain countries.…”
Section: Public Health Concernsmentioning
confidence: 99%
“…The impact of antimicrobial resistance (AMR) estimated as deaths per year is projected as even higher than cancer disorders and increases the general healthcare costs considerably. Drug prescription based on the symptoms is performed commonly, but inappropriate antimicrobial treatment is one of the reasons for antimicrobial resistance to develop ( Mendelson and Matsoso, 2015 ; Dadgostar, 2019 ; Jiang and Chen, 2020 ). The antibiotics for suspected UTI infections consist of approximately 15.0% of all prescribed antibacterial drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Infections caused by resistant organisms can be difficult to treat and tend to increase the costs associated with hospitalizations. 1,2 In Latin America, an increase in resistance by Escherichia coli and Klebsiella pneumoniae, among other bacteria of clinical relevance has been reported. 3 Specifically, in Costa Rica, multiple resistant strains have been detected.…”
Section: Introductionmentioning
confidence: 99%
“…Antimicrobial resistance is a threat to public health worldwide. Infections caused by resistant organisms can be difficult to treat and tend to increase the costs associated with hospitalizations 1,2 …”
Section: Introductionmentioning
confidence: 99%